Risk factors for loss to follow‐up after the start of direct‐acting antiviral treatment for hepatitis C virus infection

Risk factors for loss to follow‐up after the start of direct‐acting antiviral treatment for hepatitis C virus infection

Abstract Background and Aim Direct‐acting antivirals (DAAs) have recently been developed to treat hepatitis C virus (HCV) infection. Additionally, interferon‐free DAA treatment has improved liver function and reduced the risk of hepatocellular carcinoma (HCC) following HCV eradication. Previous stud...

Full description

Bibliographic Details
Main Authors: Akifumi Kuwano, Masayoshi Yada, Kazuki Kurosaka, Kosuke Tanaka, Akihide Masumoto, Kenta Motomura
Format: Article
Language:English
Published: Wiley 2023-02-01
Series:JGH Open
Subjects:
direct‐acting antivirals
glecaprevir and pibrentasvir
hepatitis C virus
history of injection drug use
loss to follow‐up
Online Access:https://doi.org/10.1002/jgh3.12855

Internet

https://doi.org/10.1002/jgh3.12855

Similar Items